Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | ENPP3 | O14638 | 7/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398917 | 0.88 | CLK1 (0.57) | CLK1NPC1SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL4394576 | 0.86 | CLK1 (0.48) | CLK1NPC1SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL4404654 | 0.86 | ENPP3 (0.62) | CLK1NPC1SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL4402171 | 0.85 | ENPP3 (0.56) | CLK1NPC1SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL13593743 | 0.85 | CLK1 (0.47) | CLK1NPC1SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL5200906 | 0.84 | ENPP3 (0.45) | CLK1NPC1SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL4394510 | 0.84 | ENPP3 (0.60) | CLK1NPC1SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL4413074 | 0.83 | CLK1 (0.52) | CLK1NPC1SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL4396704 | 0.82 | CLK1 (0.51) | CLK1NPC1SMN1; SMN2ALDH1A1USP2 | |
| Hydrochloric Acid SCHEMBL4396688 | 0.82 | CLK1 (0.51) | CLK1NPC1SMN1; SMN2ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | claimed |
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | disclosed |
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | disclosed |
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| EP-1745044-A2 | BENZOTHIAZOLE DERIVATIVES HAVING CDK MODULATING ACTIVITY AND USE THEREOF AS ANTICANCER AGENTS | Aventis Pharma S.A. (FR) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005097787-A2 | NOVEL BENZOTHIAZOLES AND THE USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA S.A. (FR) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | TFEB, ABAT, BRD4 | CLK1 2705/4885NPC1 600/4885SMN1; SMN2 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.